Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Apr;77(4):1405–1408. doi: 10.1172/JCI112450

Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

L M Slater, P Sweet, M Stupecky, S Gupta
PMCID: PMC424510  PMID: 3457021

Abstract

The development of drug resistance by tumor cells is a major obstacle to the cure of human malignancy. Cyclosporin A (CsA) completely reverses primary resistance to vincristine and cross resistance to daunorubicin in a pleiotropic drug-resistant subline of human T cell acute lymphatic leukemia. This subline is over 50-fold resistant to vincristine and fivefold resistant to daunorubicin. CsA has little effect on vincristine or daunorubicin activity in drug-sensitive parental leukemia and corrects daunorubicin resistance without altering cellular daunorubicin accumulation.

Full text

PDF
1405

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson K., Britton K., Biggs J. Distribution and concentration of cyclosporin in human blood. J Clin Pathol. 1984 Oct;37(10):1167–1171. doi: 10.1136/jcp.37.10.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beck W. T. Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts. Cancer Treat Rep. 1983 Oct;67(10):875–882. [PubMed] [Google Scholar]
  3. Colombani P. M., Robb A., Hess A. D. Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes. Science. 1985 Apr 19;228(4697):337–339. doi: 10.1126/science.3885394. [DOI] [PubMed] [Google Scholar]
  4. Griffith B. P., Hardesty R. L., Trento A., Lee A., Bahnson H. T. Targeted blood levels of cyclosporin for cardiac transplantation. J Thorac Cardiovasc Surg. 1984 Dec;88(6):952–957. [PubMed] [Google Scholar]
  5. Kennedy M. S., Deeg H. J., Storb R., Doney K., Sullivan K. M., Witherspoon R. P., Appelbaum F. R., Stewart P., Sanders J., Buckner C. D. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. Am J Med. 1985 Jun;78(6 Pt 1):978–983. doi: 10.1016/0002-9343(85)90221-9. [DOI] [PubMed] [Google Scholar]
  6. Kessel D., Wilberding C. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Res. 1985 Apr;45(4):1687–1691. [PubMed] [Google Scholar]
  7. Kessel D., Wilberding C. Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs. Cancer Treat Rep. 1985 Jun;69(6):673–676. [PubMed] [Google Scholar]
  8. LeGrue S. J., Friedman A. W., Kahan B. D. Binding of cyclosporine by human lymphocytes and phospholipid vesicles. J Immunol. 1983 Aug;131(2):712–718. [PubMed] [Google Scholar]
  9. Murray S. L., Du Vall E. M., Slater L. M. Calcium modifies the accumulation and retention of daunorubicin by Ehrlich ascites carcinoma. Cancer Chemother Pharmacol. 1984;13(1):69–70. doi: 10.1007/BF00401452. [DOI] [PubMed] [Google Scholar]
  10. Slater L. M., Murray S. L., Wetzel M. W., Sweet P., Stupecky M. Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance. Cancer Chemother Pharmacol. 1986;16(1):50–54. doi: 10.1007/BF00255285. [DOI] [PubMed] [Google Scholar]
  11. Slater L. M., Murray S. L., Wetzel M. W., Wisdom R. M., DuVall E. M. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest. 1982 Nov;70(5):1131–1134. doi: 10.1172/JCI110702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Takemoto D., Jilka C. Increased content of calmodulin in human leukemia cells. Leuk Res. 1983;7(1):97–100. doi: 10.1016/0145-2126(83)90062-0. [DOI] [PubMed] [Google Scholar]
  13. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982 Nov;42(11):4730–4733. [PubMed] [Google Scholar]
  14. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981 May;41(5):1967–1972. [PubMed] [Google Scholar]
  15. Tsuruo T., Iida H., Yamashiro M., Tsukagoshi S., Sakurai Y. Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem Pharmacol. 1982 Oct 1;31(19):3138–3140. doi: 10.1016/0006-2952(82)90097-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES